Фармакодинамические эффекты никотинового спрея для ротовой полости и таблеток цитизина: исследование у взрослых здоровых курильщиков
- Авторы: McCaffrey V.1, Hansson A.2, Perfekt R.3
-
Учреждения:
- Consumer Health Products Department, “Consumer Products Department Johnson & Johnson ЕМЕА”
- Global Clinical Pharmacology, “McNeil AB”
- Quantitative Sciences, “McNeil AB”
- Выпуск: Том 21, № 11 (2019)
- Страницы: 28-33
- Раздел: Статьи
- URL: https://journal-vniispk.ru/2075-1753/article/view/96778
- DOI: https://doi.org/10.26442/20751753.2019.11.190254
- ID: 96778
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Victoria McCaffrey
Consumer Health Products Department, “Consumer Products Department Johnson & Johnson ЕМЕА”Maidenhead, Great Britain
Anna Hansson
Global Clinical Pharmacology, “McNeil AB”
Email: *ahansson@its.jnj.com
Helsingborg, Sweden
Roland Perfekt
Quantitative Sciences, “McNeil AB”Helsingborg, Sweden
Список литературы
- Taggar J.S, Lewis S, Docherty G et al. Do cravings predict smoking cessation in smokers calling a national quit line: secondary analyses from a randomised trial for the utility of “urges to smoke” measures. Subst Abuse Treat Prev Policy 2015; 10: 15.
- Piasecki T. Relapse to smoking. Clin Psychol Rev 2006; 26: 196-215.
- Swan G, Ward M.M, Jack L.M. Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav 1996; 21 (4): 481-90.
- Shiffman S. Refining models of dependence: Variations across persons and situations. Br J Addict 1991; 86: 611-5.
- Shiffman S, Hickcox M, Paty J.A et al. Individual differences in the context of smoking lapse episodes. Addict Behav 1997; 22 (6): 797-811.
- Fidler J.A, West R. Enjoyment of smoking and urges to smoke as predictors of attempts and success of attempts to stop smoking: a longitudinal study. Drug Alcohol Depend 2011; 115 (1-2): 30-4.
- Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83 (4): 531-41.
- Piper M., Federman E.B, McCarthy D.E et al. Using medication models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol 2008; 117: 94-105.
- McCarthy D.E, Piasecki T.M, Lawrence D.L et al. Psychological Mediators of Bupropion SR Treatment for Smoking Cessation. Addiction (Abingdon, England) 2008; 103 (9): 1521-33.
- Ferguson S.G, Shiffman S, Gwaltney C.J. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 2006; 74 (6): 1153-61.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.: American Psychiatric Association, 2013; p. 571-7.
- Hartmann-Boyce J, Chepkin S.C, Ye W et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5: CD000146.
- Etter J, Stapleton J.A. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco Control 2006; 15 (4): 280-5.
- Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. Int J Health Sci 2016; 10 (3): 425-35.
- Garvey A.J, Kinnunen T, Nordstrom B.L et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2000; 2: 53-63.
- Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 2007; 102: 809-14.
- Tønnesen P, Paoletti P, Gustavsson G et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13 (2): 238-46.
- Balmford J, Borland R, Hammond D, Cummings K.M. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nic Tob Res 2011; 13: 94-102.
- Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open 2012; 2: e001618.
- Prochaska J.J, Das S, Benowitz N.L. Cytisine, the world's oldest smoking cessation aid. BMJ 2013; 347: f5198.
- Jeong S.H, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an a4 b2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal 2015; 7 (6): 475-82.
- Ravva P, Gastonguay M.R, Faessel H.M et al. Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. Nicotine Tob Res 2015; 17 (1): 106-13.
- Hansson A, Rasmussen T, Kraiczi H. Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. Nicotine Tob Res 2017; 19 (4): 477-83.
- Shiffman S, Hickcox M, Paty J.A et al. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996; 64 (5): 993-1002.
Дополнительные файлы
